Abstract |
The pathogenesis of psoriatic arthritis (PsA) is still under discussion but great advances have been made in the last 2 decades that confirm the central role of tumor necrosis factor-α (TNF-α) in its inflammatory milieu. New therapeutic approaches have been proposed, and new molecules with anti-TNF-α activity have been chemically altered to improve their pharmacological properties. Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF that has been shown clinically to be effective in the treatment of rheumatoid arthritis (RA), skin psoriasis, and PsA. This article summarizes available data on its clinical efficacy and safety profile in the treatment of patients with PsA.
|
Authors | Alberto Cauli, Matteo Piga, Ennio Lubrano, Antonio Marchesoni, Alberto Floris, Alessandro Mathieu |
Journal | The Journal of rheumatology. Supplement
(J Rheumatol Suppl)
Vol. 93
Pg. 70-2
(Nov 2015)
ISSN: 0380-0903 [Print] Canada |
PMID | 26523062
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antirheumatic Agents
- Biological Products
- Tumor Necrosis Factor-alpha
- Certolizumab Pegol
|
Topics |
- Antirheumatic Agents
(adverse effects, therapeutic use)
- Arthritis, Psoriatic
(diagnosis, drug therapy, immunology)
- Biological Products
(adverse effects, therapeutic use)
- Certolizumab Pegol
(adverse effects, therapeutic use)
- Humans
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors, immunology)
|